Dr. Bharat Aggarwal
Ph.D.
Scientific Advisor
- • Co-discovered TNF-a and TNF-b at Genentech
- • Pioneer in inflammation, NF-kappaB and STAT3 cancer research at MD Anderson
- • Foundational work led to Humira (anti-TNF-a, $10B+ annual revenue)
- • Decades-long career bridging industry and academia
Biography
Dr. Bharat Aggarwal started his career with a start-up company, Genentech, where he worked for almost ten years and his work led to the discovery of TNF-a and TNF-b, and identification of their receptors. Humira, an antibody against TNF-a, is a blockbuster biologic drug with annual revenue of more than $10 billion USD. In 1989, when Dr. Aggarwal joined M. D. Anderson, his group focused on the role of inflammatory pathways mediated through TNFs, RANK, TRAIL, CXCR4, NF-kappaB, and STAT3, for the prevention and therapy of cancer and other chronic diseases.
Professional Experience
- M. D. Anderson Cancer Center (1989 - present), inflammation and cancer research
- Genentech (~10 years), discovery of TNF-a, TNF-b and their receptors
Education
- Ph.D.